We asked our writers to name some of their favourite stocks to buy this November. Below is what they came up with.
Tom Richardson: ResMed Inc. (CHESS) (ASX: RMD)
I've recommended this California-based healthcare company twice before and not for nothing either. ResMed's seemingly bulletproof revenue growth is thanks to its market-leading products, narrow moat, and large addressable markets. Moreover, it's run by a founding family fixated on the long-term as demonstrated by its move into the software-as-service and cloud-connected home health monitoring space. The ASX scrip sells for $11 and a return to double-digit (or margin) growth in FY18 justifies a valuation around 28x trailing FX-adjusted earnings.
Motley Fool contributor Tom Richardson owns shares in ResMed Inc.
Tristan Harrison: Magellan Global Trust (ASX: MGG)
Magellan Global Trust is the new kid on the block. It's following in the footsteps of Magellan's unlisted fund by investing in global winners like Google, Apple, and others. I think it's important for Aussie investors to get a certain amount of exposure to overseas investments. The trust structure gives the flexibility for investors to receive a good amount of income along with capital growth.
It should be one of the higher-performing investment vehicles over the next decade with exposure to truly great global businesses.
Motley Fool contributor Tristan Harrison owns shares of Magellan Global Trust.
Ian Crane: TPG Telecom Ltd (ASX: TPM)
Shares in telecommunications provider TPG have rallied 6% since rival Telstra's AGM on 17 October.
Then, Telstra's chairman warned investors that TPG loomed as a "formidable competitor" set to become Australia's 4th mobile network carrier in 2018. TPG's entry into the mobile market appears timed to capitalise on the rollout of the 5G mobile standard, a technology that is expected to deliver data transmission speeds superior to that of the NBN. Market sentiment may have turned positive for TPG, following Prime Minister Malcolm Turnbull's comments that NBN had been a "calamitous train wreck".
Motley Fool contributor Ian Crane own shares in TPG Telecom Ltd.
Nivine Bazzi: Aristocrat Leisure Limited (ASX: ALL)
Sydney-based Aristocrat Leisure is one of the world's leading providers of gaming solutions. Shares have skyrocketed over 50% over the past year, however there's still room for growth. Especially following the acquisition of Israeli social gaming company Plarium Global, which will strengthen Aristocrat's presence in the high-growth mobile gaming market and increase pro-forma earnings.
Analysts have forecast a 27% price return and the company has a ROE of 40% this year, almost 4x the industry average. Given its expansion plans and recent gains, I expect it to provide strong returns.
Motley Fool contributor Nivine Bazzi has no financial interest in Aristocrat Leisure shares.
Steve Holland: Reece Ltd (ASX: REH)
Reece is not the most exciting stock on the market. But that's partly why I like it.
Reece reported an after tax profit of $212 million for FY17, up 10% on the previous year. The bathroom hardware business expects net profit after tax for the period ending 31 December 2017 to be 8% above the previous year. As a customer I've dealt with Reece for 10 years. I find its products are good quality and they stand by them. I think Reece represents a sound long-term investment.
Motley Fool contributor Steve Holland has no financial interest in Reece Ltd.
Chris Coe: Praemium Ltd (ASX: PPS)
Praemium is an innovative company in the investment platforms industry. The company had a great quarter to September, with record quarterly inflows of $749 million, record Australian inflows of $578 million and funds under administration (FUA) of $6.6 billion.
Being a software company, Praemium has a good operating margin and the increasing FUA will boost earnings. The company has no debt and cash on hand of $9 million as at 30th of June. The share price has increased 43% in October.
Motley Fool contributor Christopher Coe has no financial position in Praemium
Kevin Gandiya: Healthscope Ltd (ASX: HSO)
In my view, the market currently does not have many quality businesses that are trading at bargain prices but Healthscope could be as close as you get to such a business.
Whilst its share price has taken a beating over the last year, its long-term prospects appear favourable. There is likely to be demand for private healthcare due to an ageing population and the government's support for private health operators. Healthscope continues to pursue growth through brownfield hospital expansion projects and it has a strong balance sheet with freehold ownership of 30 of its hospital.
Motley Fool contributor Kevin Gandiya has no financial interest in Healthscope Ltd.
